VEGFA and non-small cell lung carcinoma: Recently, the results of a randomized, double-blind phase III study of erlotinib with ramucirumab (anti-VEGF therapy) or placebo in previously untreated EGFR-mutant metastatic non-small-cell lung cancer (RELAY) were reported, and the doublet therapy showed clinical benefit and results were positive [45].